{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:18:32Z","timestamp":1788412712163,"version":"build-2803163510"},"reference-count":243,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40119-026-00460-w","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:51:48Z","timestamp":1783446708000},"page":"407-438","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The \u2018Chloride Theory\u2019 for Heart Failure Pathophysiology: An Updated Narrative Review 2025"],"prefix":"10.1007","volume":"15","author":[{"given":"Hajime","family":"Kataoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"460_CR1","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1172\/JCI112456","volume":"77","author":"RJ Cody","year":"1986","unstructured":"Cody RJ, Covit AB, Schaer GL, Laragh JH, Sealey JE, Feldschuh J. Sodium and water balance in chronic congestive heart failure. J Clin Invest. 1986;77:1441\u201352.","journal-title":"J Clin Invest"},{"issue":"part 1","key":"460_CR2","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1161\/01.CIR.88.4.1620","volume":"88","author":"M Volpe","year":"1993","unstructured":"Volpe M, Tritto C, DeLuca N, et al. Abnormalities of sodium handling and of cardiovascular adaptations during high salt diet in patients with mild heart failure. Circulation. 1993;88(part 1):1620\u20137.","journal-title":"Circulation"},{"key":"460_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.933215","volume":"9","author":"Z Abassi","year":"2022","unstructured":"Abassi Z, Khoury EE, Karram T, Aronson D. Edema formation in congestive heart failure and the underlying mechanisms. Front Cardiovasc Med. 2022;9:933215.","journal-title":"Front Cardiovasc Med"},{"key":"460_CR4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.7326\/0003-4819-113-2-155","volume":"113","author":"RW Schrier","year":"1990","unstructured":"Schrier RW. Body fluid volume regulation in health and disease: a unifying hypothesis. Ann Intern Med. 1990;113:155\u20139.","journal-title":"Ann Intern Med"},{"key":"460_CR5","doi-asserted-by":"publisher","first-page":"147032031772991","DOI":"10.1177\/1470320317729919","volume":"18","author":"P Nijst","year":"2017","unstructured":"Nijst P, Verbrugge FH, Martens P, et al. Plasma renin activity in patients with heart failure and reduced ejection fraction on optimal medical therapy. J Renin Angiotensin Aldosterone Syst. 2017;18:1470320317729919.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"460_CR6","first-page":"6","volume":"10","author":"H Kataoka","year":"2019","unstructured":"Kataoka H. Rational of the \u201cchloride theory\u201d as an explanation for neurohormonal activity in heart failure pathophysiology: literature review. J Clin Exp Cardiolog. 2019;10:6.","journal-title":"J Clin Exp Cardiolog"},{"key":"460_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ijcard.2021.10.149","volume":"345","author":"J Biegus","year":"2021","unstructured":"Biegus J, Nawrocka-Millward S, Zymli\u0144ski R, et al. Distinct renin\/aldosterone activity profiles correlate with renal function, natriuretic response, decongestive ability and prognosis in acute heart failure. Int J Card. 2021;345:54\u201360.","journal-title":"Int J Card"},{"key":"460_CR8","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1002\/ejhf.70081","volume":"27","author":"J Maz\u00f3n-Ruiz","year":"2025","unstructured":"Maz\u00f3n-Ruiz J, Banegas-Deras EJ, Fern\u00e1ndez-Rodr\u00edguez JM, et al. The chloride paradigm shift in heart failure: from neglected ion to keystone of precision diuretic therapy. Eur J Heart Fail. 2025;27:3084\u201395.","journal-title":"Eur J Heart Fail"},{"key":"460_CR9","first-page":"904","volume":"9","author":"AJL Zandijk","year":"2021","unstructured":"Zandijk AJL, van Norel MR, Julius FEC, et al. Chloride in heart failure: the neglected electrolyte. J Am Coll Cardiol HF. 2021;9:904\u201315.","journal-title":"J Am Coll Cardiol HF"},{"key":"460_CR10","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.ijcard.2016.12.059","volume":"230","author":"H Kataoka","year":"2017","unstructured":"Kataoka H. Vascular expansion during worsening of heart failure: effects on clinical features and its determinants. Int J Cardiol. 2017;230:556\u201361.","journal-title":"Int J Cardiol"},{"key":"460_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.cardfail.2018.09.014","volume":"25","author":"H Kataoka","year":"2019","unstructured":"Kataoka H. Biochemical determinants of changes in plasma volume after decongestion therapy for worsening heart failure. J Card Fail. 2019;25:213\u20137.","journal-title":"J Card Fail"},{"key":"460_CR12","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.mehy.2017.06.005","volume":"104","author":"H Kataoka","year":"2017","unstructured":"Kataoka H. The \u2018chloride theory\u2019, a unifying hypothesis for renal handling and body fluid distribution in heart failure pathophysiology. Med Hypotheses. 2017;104:170\u20133.","journal-title":"Med Hypotheses"},{"key":"460_CR13","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/ehf2.12191","volume":"4","author":"H Kataoka","year":"2017","unstructured":"Kataoka H. Proposal for heart failure progression based on the \u201cchloride theory\u201d: worsening heart failure with increased vs. non-increased serum chloride concentration. ESC Heart Fail. 2017;4:623\u201331.","journal-title":"ESC Heart Fail"},{"key":"460_CR14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s40119-021-00238-2","volume":"10","author":"H Kataoka","year":"2021","unstructured":"Kataoka H. Chloride in heart failure syndrome: its pathophysiologic role and clinical implication. Cardiol Ther. 2021;10:407\u201328.","journal-title":"Cardiol Ther"},{"key":"460_CR15","first-page":"R263","volume":"274","author":"J Schnermann","year":"1998","unstructured":"Schnermann J. Juxtaglomerular cell complex in the regulation of renal salt excretion. Am J Physiol. 1998;274:R263-279.","journal-title":"Am J Physiol"},{"key":"460_CR16","doi-asserted-by":"publisher","first-page":"F587","DOI":"10.1152\/ajprenal.00130.2018","volume":"316","author":"JL Rein","year":"2019","unstructured":"Rein JL, Coca SG. \u201cI don\u2019t get no respect\u201d: the role of chloride in acute kidney injury. Am J Physiol Renal Physiol. 2019;316:F587-605.","journal-title":"Am J Physiol Renal Physiol"},{"key":"460_CR17","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1253\/circrep.CR-20-0018","volume":"2","author":"H Kataoka","year":"2020","unstructured":"Kataoka H. Effusion-serum chloride gradient in heart failure-associated pleural effusion: pathophysiologic implication. Circ Rep. 2020;2:357\u201363.","journal-title":"Circ Rep"},{"key":"460_CR18","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/00365513.2018.1466607","volume":"78","author":"H Kataoka","year":"2018","unstructured":"Kataoka H. Changes in red blood cell volume during transition of heart failure status: a reflection of cellular hydration status? Scand J Clin Lab Invest. 2018;78:305\u201311.","journal-title":"Scand J Clin Lab Invest"},{"key":"460_CR19","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ijcard.2017.11.024","volume":"252","author":"JL Grodin","year":"2018","unstructured":"Grodin JL, Mullens W, Dupont M, et al. Hemodynamic factors associated with serum chloride in ambulatory patients with advanced heart failure. Int J Cardiol. 2018;252:112\u20136.","journal-title":"Int J Cardiol"},{"key":"460_CR20","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/ehf2.13840","volume":"9","author":"M Seo","year":"2022","unstructured":"Seo M, Watanabe T, Yamada T, et al. Prognostic significance of serum chloride level in heart failure patients with preserved ejection fraction. ESC Heart Fail. 2022;9:1444\u201353.","journal-title":"ESC Heart Fail"},{"key":"460_CR21","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1002\/ehf2.13927","volume":"9","author":"H Kataoka","year":"2022","unstructured":"Kataoka H. Mechanistic insights into chloride-related heart failure progression according to the plasma volume status. ESC Heart Fail. 2022;9:2044\u20138.","journal-title":"ESC Heart Fail"},{"key":"460_CR22","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1161\/01.CIR.9.5.706","volume":"9","author":"SJ Sarnoff","year":"1954","unstructured":"Sarnoff SJ, Berglund E. Ventricular function: Starling\u2019s law of the heart studied by means of simultaneous right and left ventricular function curves in the dog. Circulation. 1954;9:706\u201318.","journal-title":"Circulation"},{"key":"460_CR23","first-page":"123","volume":"6","author":"H Kataoka","year":"2021","unstructured":"Kataoka H. Clinical significance of spot urinary chloride concentration measurements in patients with acute heart failure: investigation on the basis of the \u2018tubulo-glomerular feedback\u2019 mechanism. Cardio Open. 2021;6:123\u201331.","journal-title":"Cardio Open"},{"key":"460_CR24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000527436","volume":"12","author":"H Kataoka","year":"2022","unstructured":"Kataoka H. Estimation of plasma renin activity on the basis of serum and urinary chloride concentrations versus sodium concentrations. Cardiorenal Med. 2022;12:205\u201313.","journal-title":"Cardiorenal Med"},{"key":"460_CR25","first-page":"94","volume":"14","author":"H Kataoka","year":"2024","unstructured":"Kataoka H. Neurohormonal activation and renal chloride avidity in acute heart failure: clinical evidence supporting the \u201cchloride theory.\u201d Cardiorenal Med. 2024;14:94\u2013104.","journal-title":"Cardiorenal Med"},{"key":"460_CR26","doi-asserted-by":"publisher","first-page":"14100","DOI":"10.1038\/s41598-024-64747-5","volume":"14","author":"S Nawrocka-Millward","year":"2024","unstructured":"Nawrocka-Millward S, Biegus J, Fudim M, et al. The role of urine chloride in acute heart failure. Sci Rep. 2024;14:14100.","journal-title":"Sci Rep"},{"key":"460_CR27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ejim.2011.11.013","volume":"23","author":"K Berend","year":"2012","unstructured":"Berend K, van Hulsteijn LH, Gans ROB. Chloride: the queen of electrolytes? Eur J Intern Med. 2012;23:203\u201311.","journal-title":"Eur J Intern Med"},{"key":"460_CR28","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/cc9052","volume":"14","author":"NM Yunos","year":"2010","unstructured":"Yunos NM, Bellomo R, Story D, Kellum J. Bench-to-bedside review: chloride in critical illness. Crit Care. 2010;14:226.","journal-title":"Crit Care"},{"key":"460_CR29","first-page":"80","volume":"17","author":"H Kataoka","year":"2018","unstructured":"Kataoka H. Treatment of hypochloremia with acetazolamide in an advanced heart failure patient and importance of monitoring urinary electrolytes. J Cardiol Cases. 2018;17:80\u20134.","journal-title":"J Cardiol Cases"},{"key":"460_CR30","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/ejhf.276","volume":"17","author":"JJ Park","year":"2015","unstructured":"Park JJ, Choi DJ, Yoon CH, et al. The prognostic value of arterial blood gas analysis in high-risk acute heart failure patients: an analysis of the Korean Heart Failure (KorHF) registry. Eur J Heart Fail. 2015;17:601\u201311.","journal-title":"Eur J Heart Fail"},{"key":"460_CR31","first-page":"399","volume":"9","author":"H Nakano","year":"2020","unstructured":"Nakano H, Nagai T, Honda Y, et al. Prognostic value of base excess as indicator of acid\u2013base balance in acute heart failure. Eur Heart J Acute Cardiovasc Care. 2020;9:399\u2013405.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"460_CR32","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s40119-020-00194-3","volume":"9","author":"JJ Cuthbert","year":"2020","unstructured":"Cuthbert JJ, Bhandari S, Clark AL. Hypochloraemia in patients with heart failure: causes and consequence. Cardiol Ther. 2020;9:333\u201347.","journal-title":"Cardiol Ther"},{"key":"460_CR33","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1093\/eurheartj\/ehad236","volume":"44","author":"P Martens","year":"2023","unstructured":"Martens P, Verbrugge FH, Dauw J, et al. Pre-treatment bicarbonate levels and decongestion by acetazolamide: the ADVOR trial. Eur Heart J. 2023;44:1995\u20132005.","journal-title":"Eur Heart J"},{"key":"460_CR34","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/14796678.2026.2612872","volume":"22","author":"H Kataoka","year":"2026","unstructured":"Kataoka H. Improvement of respiratory function with acetazolamide in heart failure: a representative case of cardio\u2013renal pulmonary syndrome. Future Cardiol. 2026;22:135\u20139.","journal-title":"Future Cardiol"},{"key":"460_CR35","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1042\/CS20150469","volume":"130","author":"M Volpe","year":"2016","unstructured":"Volpe M, Carnovali M, Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci. 2016;130:57\u201377.","journal-title":"Clin Sci"},{"key":"460_CR36","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.52768\/AnnCardiolVascMed\/1087","volume":"8","author":"H Kataoka","year":"2025","unstructured":"Kataoka H. Counteraction of the natriuretic peptide and the renin\u2013angiotensin\u2013aldosterone systems in acute heart failure. Ann Cardiol Vasc Med. 2025;8:1087.","journal-title":"Ann Cardiol Vasc Med"},{"key":"460_CR37","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1136\/gut.43.2.294","volume":"43","author":"GI Sandle","year":"1998","unstructured":"Sandle GI. Salt and water absorption in the human colon: a modern appraisal. Gut. 1998;43:294\u20139.","journal-title":"Gut"},{"key":"460_CR38","doi-asserted-by":"publisher","first-page":"R1294","DOI":"10.1152\/ajpregu.00738.2005","volume":"290","author":"M Damgaard","year":"2006","unstructured":"Damgaard M, Norsk P, Gustafsson F, et al. Hemodynamic and neuroendocrine responses to changes in sodium intake in compensated heart failure. Am J Physiol Regul Integr Comp Physiol. 2006;290:R1294-1301.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"460_CR39","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/ejhf.3244","volume":"26","author":"W Mullens","year":"2024","unstructured":"Mullens W, Damman K, Dhont S, et al. Dietary sodium and fluid intake in heart failure: a clinical consensus statement of the Heart Failure Association of the ESC. Eur J Heart Fail. 2024;26:730\u201341.","journal-title":"Eur J Heart Fail"},{"key":"460_CR40","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jacc.2022.11.023","volume":"81","author":"SJ Greene","year":"2023","unstructured":"Greene SJ, Bauersachs J, Brugts JJ, et al. Worsening heart failure: nomenclature, epidemiology, and future directions. J Am Coll Cardiol. 2023;81:413\u201324.","journal-title":"J Am Coll Cardiol"},{"key":"460_CR41","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s10741-025-10497-z","volume":"30","author":"C Fonseca","year":"2025","unstructured":"Fonseca C, Baptista R, Franco F, et al. Worsening heart failure: progress, pitfalls, and perspectives. Heart Fail Rev. 2025;30:715\u201334.","journal-title":"Heart Fail Rev"},{"key":"460_CR42","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/02813432.2020.1844387","volume":"38","author":"JM Verdu-Rotellar","year":"2020","unstructured":"Verdu-Rotellar JM, Vaillant-Roussel H, Abellana R, et al. Precipitating factors of heart failure decompensation, short-term morbidity and mortality in patients attended in primary care. Scand J Prim Health Care. 2020;38:473\u201380.","journal-title":"Scand J Prim Health Care"},{"key":"460_CR43","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/ejhf.268","volume":"17","author":"JL Grodin","year":"2015","unstructured":"Grodin JL, Mullens W, Dupont M, et al. Prognostic role of cardiac power index in ambulatory patients with advanced heart failure. Eur J Heart Fail. 2015;17:689\u201396.","journal-title":"Eur J Heart Fail"},{"key":"460_CR44","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1002\/ejhf.1492","volume":"21","author":"O Chioncel","year":"2019","unstructured":"Chioncel O, Mebazaa A, Maggioni AP, et al. Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes: insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. 2019;21:1338\u201352.","journal-title":"Eur J Heart Fail"},{"key":"460_CR45","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jacc.2014.12.010","volume":"65","author":"FH Verbrugge","year":"2015","unstructured":"Verbrugge FH, Steels P, Grieten L, Nijst P, Tang WH, Mullens W. Hyponatremia in acute decompensated heart failure: depletion versus dilution. J Am Coll Cardiol. 2015;65:480\u201392.","journal-title":"J Am Coll Cardiol"},{"key":"460_CR46","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/0002-9343(88)90265-3","volume":"84","author":"RA Rosen","year":"1988","unstructured":"Rosen RA, Julian BA, Dubovsky EV, Galla JH, Luke RG. On the mechanism by which chloride corrects metabolic alkalosis in man. Am J Med. 1988;84:449\u201358.","journal-title":"Am J Med"},{"key":"460_CR47","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1093\/eurheartj\/ehw008","volume":"37","author":"M Valentova","year":"2016","unstructured":"Valentova M, von Haehling S, Bauditz J, et al. Intestinal congestion and right ventricular dysfunction: a link with appetite loss, inflammation, and cachexia in chronic heart failure. Eur Heart J. 2016;37:1684\u201391.","journal-title":"Eur Heart J"},{"key":"460_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2023.131672","volume":"399","author":"Z Tan","year":"2024","unstructured":"Tan Z, Liu Y, Hong K. The association between serum chloride and mortality in ICU patients with heart failure: the impact of bicarbonate. Int J Cardiol. 2024;399:131672.","journal-title":"Int J Cardiol"},{"key":"460_CR49","first-page":"F321","volume":"236","author":"RW Schrier","year":"1979","unstructured":"Schrier RW, Berl T, Anderson RJ. Osmotic and nonosmotic control of vasopressin release. Am J Physiol. 1979;236:F321-332.","journal-title":"Am J Physiol"},{"key":"460_CR50","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1253\/circj.CJ-14-0368","volume":"78","author":"T Imamura","year":"2014","unstructured":"Imamura T, Kinugawa K, Hatano M, et al. Low cardiac output stimulates vasopressin release in patients with stage D heart failure: its relevance to poor prognosis and reversal by surgical treatment. Circ J. 2014;78:2259\u201367.","journal-title":"Circ J"},{"key":"460_CR51","first-page":"270","volume":"14","author":"J Van den Eynde","year":"2024","unstructured":"Van den Eynde J, Verbrugge FH. Renal sodium avidity in heart failure. Cardiorenal Med. 2024;14:270\u201380.","journal-title":"Cardiorenal Med"},{"key":"460_CR52","first-page":"132","volume":"6","author":"H Kataoka","year":"2021","unstructured":"Kataoka H. Plasma renin activity after diuretic treatment in patients with stable heart failure: with special reference to its association with electrolyte chloride. Cardio Open. 2021;6:132\u201342.","journal-title":"Cardio Open"},{"key":"460_CR53","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1002\/ejhf.1607","volume":"21","author":"RJ Rachwan","year":"2019","unstructured":"Rachwan RJ, Butler J, Collins SP, et al. Is plasma renin activity associated with worse outcomes in acute heart failure?: a secondary analysis from the BLAST-AHF trial. Eur J Heart Fail. 2019;21:1561\u201370.","journal-title":"Eur J Heart Fail"},{"key":"460_CR54","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/8883145","author":"E Han","year":"2023","unstructured":"Han E, Prausm\u00fcller S, Weidenhammer A, et al. Renin trajectories and outcome in stable heart failure with reduced ejection fraction (HFrEF) on contemporary therapy: a monocentric study from an Austrian tertiary hospital outpatient clinic. J Renin Angiotensin Aldosterone Syst. 2023. https:\/\/doi.org\/10.1155\/2023\/8883145.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"460_CR55","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/ejhf.1369","volume":"21","author":"W Mullens","year":"2019","unstructured":"Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21:137\u201355.","journal-title":"Eur J Heart Fail"},{"key":"460_CR56","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s40119-020-00172-9","volume":"9","author":"H Kataoka","year":"2020","unstructured":"Kataoka H. Proposal for new classification and practical use of diuretics according to their effects on the serum chloride concentration: rationale based on the \u2018chloride theory\u2019. Cardiol Ther. 2020;9:227\u201344.","journal-title":"Cardiol Ther."},{"key":"460_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2023.100614","volume":"5","author":"N Arora","year":"2023","unstructured":"Arora N. Serum chloride and heart failure. Kidney Med. 2023;5:100614.","journal-title":"Kidney Med"},{"key":"460_CR58","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41569-020-0379-7","volume":"17","author":"EM Boorsma","year":"2020","unstructured":"Boorsma EM, ter Maaten JM, Damman K, et al. Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment. Nat Rev Cardiol. 2020;17:641\u201355.","journal-title":"Nat Rev Cardiol"},{"key":"460_CR59","doi-asserted-by":"publisher","first-page":"16629","DOI":"10.20452\/pamw.16629","volume":"133","author":"H Kataoka","year":"2023","unstructured":"Kataoka H. Acetazolamide as a potent chloride-regaining diuretic: time to re-evaluate its diverse actions. Pol Arch Intern Med. 2023;133:16629.","journal-title":"Pol Arch Intern Med"},{"key":"460_CR60","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jchf.2019.10.012","volume":"8","author":"M Griffin","year":"2020","unstructured":"Griffin M, Soufer A, Goljo E, et al. Real world use of hypertonic saline in refractory acute decompensated heart failure: a U.S. center\u2019s experience. JACC Heart Fail. 2020;8:199\u2013208.","journal-title":"JACC Heart Fail"},{"key":"460_CR61","doi-asserted-by":"publisher","first-page":"4174","DOI":"10.1002\/ehf2.13511","volume":"8","author":"A Tuttolomondo","year":"2021","unstructured":"Tuttolomondo A, Maida C, Casuccio A, et al. Effects of intravenous furosemide plus small-volume hypertonic saline solutions on marker of heart failure. ESC Heart Fail. 2021;8:4174\u201386.","journal-title":"ESC Heart Fail"},{"key":"460_CR62","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1161\/CIRCULATIONAHA.119.045409","volume":"142","author":"FH Verbrugge","year":"2020","unstructured":"Verbrugge FH, Guazzi M, Testani JM, Borlaug BA. Altered hemodynamics and end-organ damage in heart failure: impact on the lung and kidney. Circulation. 2020;142:998\u20131012.","journal-title":"Circulation"},{"key":"460_CR63","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1053\/j.akdh.2022.12.002","volume":"30","author":"A Koirala","year":"2023","unstructured":"Koirala A, Pourafshar N, Daneshmand A, Wilcox CS, Mannemuddhu SS, Arora N. Etiology and management of edema: a review. Adv Kidney Dis Health. 2023;30:110\u201323.","journal-title":"Adv Kidney Dis Health"},{"key":"460_CR64","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s11897-016-0295-7","volume":"13","author":"JL Grodin","year":"2016","unstructured":"Grodin JL. Pharmacologic approaches to electrolyte abnormalities in heart failure. Curr Heart Fail Rep. 2016;13:181\u20139.","journal-title":"Curr Heart Fail Rep"},{"key":"460_CR65","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.94","volume":"1","author":"H Kataoka","year":"2018","unstructured":"Kataoka H. Dynamic changes in serum chloride concentrations during worsening of heart failure and its recovery following conventional diuretic therapy: a single-center study. Health Sci Rep. 2018;1:e94.","journal-title":"Health Sci Rep"},{"key":"460_CR66","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1067\/mhj.2000.110933","volume":"140","author":"C Lucas","year":"2000","unstructured":"Lucas C, Johnson W, Hamilton MA, et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J. 2000;140:840\u20137.","journal-title":"Am Heart J"},{"key":"460_CR67","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ijcard.2018.01.067","volume":"258","author":"J Rubio-Gracia","year":"2018","unstructured":"Rubio-Gracia J, Demissei BG, Ter Maaten JM, et al. Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. Int J Cardiol. 2018;258:185\u201391.","journal-title":"Int J Cardiol"},{"key":"460_CR68","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1161\/CIRCULATIONAHA.109.933275","volume":"122","author":"JM Testani","year":"2010","unstructured":"Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation. 2010;122:265\u201372.","journal-title":"Circulation"},{"key":"460_CR69","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1161\/CIRCHEARTFAILURE.111.963413","volume":"5","author":"M Metra","year":"2012","unstructured":"Metra M, Davison B, Bettari L, et al. Is worsening renal function an ominous prognostic sign in patients with acute heart failure?: the role of congestion and its interaction with renal function. Circ Heart Fail. 2012;5:54\u201362.","journal-title":"Circ Heart Fail"},{"key":"460_CR70","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/ejhf.2384","volume":"24","author":"JE Emmens","year":"2022","unstructured":"Emmens JE, ter Maaten JM, Matsue Y, et al. Worsening renal function in acute heart failure in the context of diuretic response. Eur J Heart Fail. 2022;24:365\u201374.","journal-title":"Eur J Heart Fail"},{"key":"460_CR71","doi-asserted-by":"publisher","first-page":"445","DOI":"10.17219\/acem\/144327","volume":"31","author":"A Kosiorek","year":"2022","unstructured":"Kosiorek A, Biegus J, Rozentryt P, Hurkacz M, Zymli\u0144ski R. Cardiorenal syndrome: decongestion in heart failure across wide spectrum of kidney pathophysiology. Adv Clin Exp Med. 2022;31:445\u201355.","journal-title":"Adv Clin Exp Med"},{"key":"460_CR72","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1161\/CIRCULATIONAHA.117.030112","volume":"137","author":"T Ahmad","year":"2018","unstructured":"Ahmad T, Jackson K, Rao VS, et al. Worsening renal function in patients with acute heart failure undergoing aggressive diuresis is not associated with tubular injury. Circulation. 2018;137:2016\u201328.","journal-title":"Circulation"},{"key":"460_CR73","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.123.011751","volume":"17","author":"S Duff","year":"2024","unstructured":"Duff S, Wettersten N, Horiuchi Y, et al. Absence of kidney tubular injury in patients with acute heart failure with acute kidney injury. Circ Heart Fail. 2024;17:e011751.","journal-title":"Circ Heart Fail"},{"key":"460_CR74","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/ejhf.1796","volume":"22","author":"C Kapelios","year":"2020","unstructured":"Kapelios C, Laroche C, Crespo-Leiro MG, et al. Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry. Eur J Heart Fail. 2020;22:1424\u201337.","journal-title":"Eur J Heart Fail"},{"key":"460_CR75","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/ejhf.3714","volume":"27","author":"C Geraeds","year":"2025","unstructured":"Geraeds C, Bruninx A, Dekker A, et al. Exploring safety of down-titrating diuretics in heart failure management. Eur J Heart Fail. 2025;27:1393\u20139.","journal-title":"Eur J Heart Fail"},{"key":"460_CR76","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1016\/j.jacc.2020.10.022","volume":"76","author":"G Rossitto","year":"2020","unstructured":"Rossitto G, Mary S, McAllister C, et al. Reduced lymphatic reserve in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2020;76:2817\u201329.","journal-title":"J Am Coll Cardiol"},{"key":"460_CR77","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s10741-024-10449-z","volume":"30","author":"B Ponikowska","year":"2025","unstructured":"Ponikowska B, Fudim M, Iwanek G, Zymli\u0144ski R, Biegus J. Harnessing the lymphatic system. Heart Fail Rev. 2025;30:673\u201383.","journal-title":"Heart Fail Rev"},{"key":"460_CR78","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.jacc.2019.12.059","volume":"75","author":"GM Felker","year":"2020","unstructured":"Felker GM, Ellison DH, Mullens W, Cox ZL, Testani JM. Diuretic therapy for patients with heart failure. J Am Coll Cardiol. 2020;75:1178\u201395.","journal-title":"J Am Coll Cardiol"},{"key":"460_CR79","first-page":"e876","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e876\u201394.","journal-title":"Circulation"},{"key":"460_CR80","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1016\/j.jacc.2017.04.042","volume":"69","author":"Y Matsue","year":"2017","unstructured":"Matsue Y, Damman K, Voors AA, et al. Time-to-furosemide treatment and mortality in patients hospitalized with acute heart failure. J Am Coll Cardiol. 2017;69:3042\u201351.","journal-title":"J Am Coll Cardiol"},{"key":"460_CR81","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ahj.2023.12.012","volume":"269","author":"TS Rodrigues","year":"2024","unstructured":"Rodrigues TS, Quarto LJ, Nogueira SC, et al. Door-to-diuretic time and mortality in patients with acute heart failure: a systemic review and meta-analysis. Am Heart J. 2024;269:205\u20139.","journal-title":"Am Heart J"},{"key":"460_CR82","volume":"3","author":"JA Jacobs","year":"2024","unstructured":"Jacobs JA, Carter SJ, Bullock G, et al. Optimal initial intravenous loop diuretic dosing in acute decompensated heart failure. J Am Coll Cardiol Adv. 2024;3:101250.","journal-title":"J Am Coll Cardiol Adv"},{"key":"460_CR83","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1002\/ejhf.1229","volume":"20","author":"JL Grodin","year":"2018","unstructured":"Grodin JL, Testani JM, Pandey A, et al. Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT. Eur J Heart Fail. 2018;20:1436\u201343.","journal-title":"Eur J Heart Fail"},{"key":"460_CR84","first-page":"883","volume":"123","author":"MI Khan","year":"1980","unstructured":"Khan MI. Treatment of refractory congestive heart failure and normokalemic hypochloremic alkalosis with acetazolamide and spironolactone. Can Med Assoc J. 1980;123:883\u20137.","journal-title":"Can Med Assoc J"},{"key":"460_CR85","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jacc.2015.06.007","volume":"66","author":"JL Grodin","year":"2015","unstructured":"Grodin JL, Simon J, Hachamovitch R, et al. Prognostic role of serum chloride levels in acute decompensated heart failure. J Am Coll Cardiol. 2015;66:659\u201366.","journal-title":"J Am Coll Cardiol"},{"key":"460_CR86","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003109","volume":"9","author":"JM ter Maaten","year":"2016","unstructured":"ter Maaten JM, Damman K, Hanberg JS, et al. Hypochloremia, diuretic resistance, and outcome in patients with acute heart failure. Circ Heart Fail. 2016;9:e003109.","journal-title":"Circ Heart Fail"},{"key":"460_CR87","first-page":"234","volume":"28","author":"C Caramelo","year":"2008","unstructured":"Caramelo C, Albalate M, Alc\u00e1zar TR, Baldov\u00ed S, P\u00e9rez AG, Mar\u00edn M. Actuality of the use of acetazolamide as a diuretic: usefulness in refractory edema and in aldosterone-antagonist-related hyperkalemia. Nefrologia. 2008;28:234\u20138.","journal-title":"Nefrologia"},{"key":"460_CR88","first-page":"58","volume":"14","author":"A Kazory","year":"2024","unstructured":"Kazory A, Ronco C, Koratala A. Cardiorenal interactions in acute heart failure: renal proximal tubules in the spotlight. Cardiorenal Med. 2024;14:58\u201366.","journal-title":"Cardiorenal Med"},{"key":"460_CR89","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3390\/jcm13010288","volume":"13","author":"M Sabina","year":"2024","unstructured":"Sabina M, Barakat Z, Feliciano A, Lamb A, Alsamman MM. Unlocking the potential of acetazolamide: a literature review of an adjunctive approach in heart failure management. J Clin Med. 2024;13:288.","journal-title":"J Clin Med"},{"key":"460_CR90","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1056\/NEJM195405132501902","volume":"250","author":"AS Relman","year":"1954","unstructured":"Relman AS, Leaf A, Schwartz WB. Oral administration of a potent carbonic anhydrase inhibitor (\u2018Diamox\u2019). N Engl J Med. 1954;250:800\u20134.","journal-title":"N Engl J Med"},{"key":"460_CR91","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s40261-017-0577-1","volume":"37","author":"T Imiela","year":"2017","unstructured":"Imiela T, Budaj A. Acetazolamide as add-on diuretic therapy in exacerbations of chronic heart failure: a pilot study. Clin Drug Investig. 2017;37:1175\u201381.","journal-title":"Clin Drug Investig"},{"key":"460_CR92","doi-asserted-by":"publisher","DOI":"10.1111\/1755-5922.12465","volume":"36","author":"J N\u00fa\u00f1ez","year":"2018","unstructured":"N\u00fa\u00f1ez J, Heredia R, Pay\u00e1 A, Sanchis I, et al. Use of acetazolamide in the treatment of patients with refractory congestive heart failure. Cardiovasc Ther. 2018;36:e12465.","journal-title":"Cardiovasc Ther"},{"key":"460_CR93","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJMoa2203094","volume":"387","author":"W Mullens","year":"2022","unstructured":"Mullens W, Dauw J, Martens P, et al. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med. 2022;387:1185\u201395.","journal-title":"N Engl J Med"},{"key":"460_CR94","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.jacc.2023.03.400","volume":"81","author":"FH Verbrugge","year":"2023","unstructured":"Verbrugge FH, Martens P, Dauw J, et al. Natriuretic response to acetazolamide in patients with acute heart failure and volume overload. J Am Coll Cardiol. 2023;81:2013\u201324.","journal-title":"J Am Coll Cardiol"},{"key":"460_CR95","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1161\/CIRCULATIONAHA.122.062486","volume":"147","author":"P Martens","year":"2023","unstructured":"Martens P, Dauw J, Verbrugge FH, et al. Decongestion with acetazolamide in acute decompensated heart failure across the spectrum of left ventricular ejection fraction: a prespecified analysis from the ADOVOR trial. Circulation. 2023;147:201\u201311.","journal-title":"Circulation"},{"key":"460_CR96","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1093\/eurheartj\/ehad557","volume":"44","author":"E Meekers","year":"2023","unstructured":"Meekers E, Dauw J, Martens P, et al. Renal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial. Eur Heart J. 2023;44:3672\u201382.","journal-title":"Eur Heart J"},{"key":"460_CR97","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1002\/ejhf.2863","volume":"25","author":"S Dhont","year":"2023","unstructured":"Dhont S, Martens P, Meekers E, et al. Sodium and potassium changes during decongestion with acetazolamide: a pre-specified analysis from the ADVOR trial. Eur J Heart Fail. 2023;25:1310\u20139.","journal-title":"Eur J Heart Fail"},{"key":"460_CR98","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1007\/s00380-019-01433-x","volume":"34","author":"H Kataoka","year":"2019","unstructured":"Kataoka H. Acetazolamide as a potent chloride-regaining diuretic: short- and long-term effects, and its pharmacologic role under the \u2018chloride theory\u2019 for heart failure pathophysiology. Heart Vessels. 2019;34:1952\u201360.","journal-title":"Heart Vessels"},{"key":"460_CR99","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000504533","volume":"145","author":"H Kataoka","year":"2020","unstructured":"Kataoka H. Comparison of changes in plasma volume and renal function between acetazolamide and conventional diuretics: understanding the mechanical differences according to the \u201cchloride theory.\u201d Cardiology. 2020;145:215\u201323.","journal-title":"Cardiology"},{"key":"460_CR100","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.123.011749","volume":"17","author":"J Van den Eynde","year":"2024","unstructured":"Van den Eynde J, Martens P, Dauw J, et al. Serum chloride and the response to acetazolamide in patients with acute heart failure and volume overload: a post hoc analysis from the ADVOR trial. Circ Heart Fail. 2024;17:e11749.","journal-title":"Circ Heart Fail"},{"key":"460_CR101","volume":"133","author":"A Kosiorek","year":"2023","unstructured":"Kosiorek A, Urban S, Detyna J, Biegus J, Hurkacz M, Zymli\u0144ski R. The diuretic, natriuretic and chloride-regaining effects of oral acetazolamide as an add-on therapy for acute heart failure with volume overload: a single-center, prospective, randomized study. Pol Arch Intern Med. 2023;133:16526.","journal-title":"Pol Arch Intern Med"},{"key":"460_CR102","volume":"16","author":"M Asif","year":"2024","unstructured":"Asif M, Malik F, Khan AS, et al. Exploring neurohormonal modulation by acetazolamide in heart failure. Cureus. 2024;16:e75786.","journal-title":"Cureus"},{"key":"460_CR103","first-page":"1","volume":"2","author":"H Kataoka","year":"2018","unstructured":"Kataoka H. Vasopressin antagonist-like effect of acetazolamide in a heart failure patient: a case report. Eur Heart J Case Rep. 2018;2:1\u20135.","journal-title":"Eur Heart J Case Rep"},{"key":"460_CR104","first-page":"1032","volume":"3","author":"H Kataoka","year":"2020","unstructured":"Kataoka H. Treatment of hyponatremia with acetazolamide in cardiovascular patients: possible alternative diuretic to vasopressin antagonists. Ann Cardio Vasc Med. 2020;3:1032.","journal-title":"Ann Cardio Vasc Med"},{"key":"460_CR105","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44:3627\u201339.","journal-title":"Eur Heart J"},{"key":"460_CR106","doi-asserted-by":"publisher","first-page":"F273","DOI":"10.1152\/ajprenal.00195.2005","volume":"290","author":"LC Costello-Boerrigter","year":"2006","unstructured":"Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006;290:F273-278.","journal-title":"Am J Physiol Renal Physiol"},{"key":"460_CR107","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/ehf2.13111","volume":"8","author":"T Kuragaichi","year":"2021","unstructured":"Kuragaichi T, Sato Y. Temporal trends of a vasopressin V2 receptor antagonists in heart failure using a nationwide database in Japan. ESC Heart Fail. 2021;8:527\u201338.","journal-title":"ESC Heart Fail"},{"key":"460_CR108","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","volume":"291","author":"M Gheorghiade","year":"2004","unstructured":"Gheorghiade M, Gattis WA, O\u2019Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963\u201371.","journal-title":"JAMA"},{"key":"460_CR109","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","volume":"297","author":"MA Konstam","year":"2007","unstructured":"Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA. 2007;297:1319\u201331.","journal-title":"JAMA"},{"key":"460_CR110","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1536\/ihj.18-119","volume":"59","author":"K Kinugawa","year":"2018","unstructured":"Kinugawa K, Sato N, Inomata T. Effects of tolvaptan on volume overload in patients with heart failure: meta-analysis of randomized controlled trials. Int Heart J. 2018;59:1368\u201377.","journal-title":"Int Heart J"},{"key":"460_CR111","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1056\/NEJMoa065181","volume":"355","author":"R Schrier","year":"2006","unstructured":"Schrier R, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099\u2013112.","journal-title":"N Engl J Med"},{"key":"460_CR112","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/j.jacc.2007.01.091","volume":"49","author":"JE Udelson","year":"2007","unstructured":"Udelson JE, McGrew FA, Flores E, et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol. 2007;49:2151\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"460_CR113","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00210-011-0713-z","volume":"385","author":"A Tahara","year":"2012","unstructured":"Tahara A, Kurosaki E, Yokono M, et al. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol. 2012;385:423\u201336.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"460_CR114","first-page":"185","volume":"14","author":"H Kataoka","year":"2016","unstructured":"Kataoka H, Yamasaki Y. Strategy for monitoring decompensated heart failure treated by an oral vasopressin antagonist with special reference to the role of serum chloride: a case report. J Cardiol Cases. 2016;14:185\u20138.","journal-title":"J Cardiol Cases"},{"key":"460_CR115","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.jjcc.2012.09.002","volume":"60","author":"K Watanabe","year":"2012","unstructured":"Watanabe K, Dohi K, Sugimoto T, et al. Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure. J Cardiol. 2012;60:462\u20139.","journal-title":"J Cardiol"},{"key":"460_CR116","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ehf2.12088","volume":"3","author":"K Jujo","year":"2016","unstructured":"Jujo K, Saito K, Ishida I, et al. Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. ESC Heart Fail. 2016;3:177\u201388.","journal-title":"ESC Heart Fail"},{"key":"460_CR117","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/ehf2.12690","volume":"7","author":"S Tamaki","year":"2020","unstructured":"Tamaki S, Yamada T, Morita T, et al. Impact of adjunctive tolvaptan on sympathetic activity in acute heart failure with preserved ejection fraction. ESC Heart Fail. 2020;7:933\u20137.","journal-title":"ESC Heart Fail"},{"key":"460_CR118","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.jacc.2008.08.013","volume":"52","author":"JE Udelson","year":"2008","unstructured":"Udelson JE, Orlandi C, Ouyang J, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol. 2008;52:1540\u20135.","journal-title":"J Am Coll Cardiol"},{"key":"460_CR119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1753944720977741","volume":"15","author":"J Urbach","year":"2021","unstructured":"Urbach J, Goldsmith SR. Vasopressin antagonism in heart failure: a review of the hemodynamic studies and major clinical trials. Ther Adv Cardiovasc Dis. 2021;15:1\u201310.","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"460_CR120","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1536\/ihj.16-023","volume":"57","author":"T Imamura","year":"2016","unstructured":"Imamura T, Kinugawa K. Tolvaptan improves the long-term prognosis in patients with congestive heart failure with preserved ejection fraction as well as in those with reduced ejection fraction. Int Heart J. 2016;57:600\u20136.","journal-title":"Int Heart J"},{"key":"460_CR121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0207481","volume":"13","author":"H Takimura","year":"2018","unstructured":"Takimura H, Hada T, Kawano M, et al. A novel validated method for predicting the risk of re-hospitalization for worsening heart failure and the effectiveness of the diuretic upgrading therapy with tolvaptan. PLoS ONE. 2018;13:1\u201314.","journal-title":"PLoS ONE"},{"key":"460_CR122","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.123.064346","volume":"148","author":"M Packer","year":"2023","unstructured":"Packer M, Wilcox CS, Testani JM. Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcome. Circulation. 2023;148:354\u201372.","journal-title":"Circulation"},{"key":"460_CR123","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1002\/ejhf.2967","volume":"25","author":"J Biegus","year":"2023","unstructured":"Biegus J, Fudim M, Salah HM, Heerspink HJL, Voors AA, Ponikowski P. Sodium-glucose cotransporter-2 inhibitors in heart failure: potential decongestive mechanisms and current clinical studies. Eur J Heart Fail. 2023;25:1526\u201336.","journal-title":"Eur J Heart Fail"},{"key":"460_CR124","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/ejhf.2066","volume":"23","author":"EM Boorsma","year":"2021","unstructured":"Boorsma EM, Beusekamp JC, ter Maaten J, et al. Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure. Eur J Heart Fail. 2021;23:68\u201378.","journal-title":"Eur J Heart Fail"},{"key":"460_CR125","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.jacc.2024.02.020","volume":"83","author":"A Marton","year":"2024","unstructured":"Marton A, Saffari SE, Rauh M, et al. Water conservation overrides osmotic diuresis during SGLT2 inhibition in patients with heart failure. J Am Coll Cardiol. 2024;83:1386\u201398.","journal-title":"J Am Coll Cardiol"},{"key":"460_CR126","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/dom.12127","volume":"15","author":"HJL Heerspink","year":"2013","unstructured":"Heerspink HJL, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15:853\u201362.","journal-title":"Diabetes Obes Metab"},{"key":"460_CR127","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","volume":"60","author":"V Vallon","year":"2017","unstructured":"Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60:215\u201325.","journal-title":"Diabetologia"},{"key":"460_CR128","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"460_CR129","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJ McMurray","year":"2019","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008.","journal-title":"N Engl J Med"},{"key":"460_CR130","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413\u201324.","journal-title":"N Engl J Med"},{"key":"460_CR131","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451\u201361.","journal-title":"N Engl J Med"},{"key":"460_CR132","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.amjms.2016.08.015","volume":"352","author":"L Chen","year":"2016","unstructured":"Chen L, LaRocque L, Efe O, Wang J, Sands JM, Klein JD. Effect of dapagliflozin treatment on fluid and electrolyte balance in diabetic rats. Am J Med Sci. 2016;352:517\u201323.","journal-title":"Am J Med Sci"},{"key":"460_CR133","doi-asserted-by":"publisher","first-page":"F653","DOI":"10.1152\/ajprenal.00143.2018","volume":"315","author":"T Masuda","year":"2018","unstructured":"Masuda T, Watanabe Y, Fukuda K, et al. Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat. Am J Physiol Renal Physiol. 2018;315:F653-664.","journal-title":"Am J Physiol Renal Physiol"},{"key":"460_CR134","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13098-020-0515-x","volume":"12","author":"H Kataoka","year":"2020","unstructured":"Kataoka H, Yoshida Y. Enhancement of the serum chloride concentration by administration of sodium\u2013glucose cotransporter-2 inhibitor and its mechanisms and clinical significance in type 2 diabetic patients: a pilot study. Diabetol Metab Syndr. 2020;12:5.","journal-title":"Diabetol Metab Syndr"},{"key":"460_CR135","first-page":"705","volume":"76","author":"T Higashikawa","year":"2022","unstructured":"Higashikawa T, Ito T, Mizuno T, et al. The impact of tofogliflozin on physiological and hormonal function, serum electrolytes, and cardiac diastolic function in elderly Japanese patients with type 2 diabetes mellitus. Acta Med Okayama. 2022;76:705\u201313.","journal-title":"Acta Med Okayama"},{"key":"460_CR136","doi-asserted-by":"publisher","DOI":"10.3390\/ph17111553","volume":"17","author":"S Genc","year":"2024","unstructured":"Genc S, Evren B, Yigit OS, et al. Evolving clinical features of diabetic ketoacidosis: the impact of SGLT2 inhibitors. Pharmaceuticals (Basel). 2024;17:1553.","journal-title":"Pharmaceuticals (Basel)"},{"key":"460_CR137","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd11110364","volume":"11","author":"I Jurin","year":"2024","unstructured":"Jurin I, Ivanovi\u0107 Mihajlovi\u0107 V, \u0160aki\u0107 Z, et al. Effects of sodium-glucose co-transporter 2 inhibitors on serum chloride concentrations in patients with heart failure. J Cardiovasc Dev Dis. 2024;11:364.","journal-title":"J Cardiovasc Dev Dis"},{"key":"460_CR138","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.cmet.2017.01.007","volume":"25","author":"M Shekarabi","year":"2017","unstructured":"Shekarabi M, Zhang J, Khanna AR, Ellison DH, Delpire E, Kahle KT. WNK kinase signaling in ion homeostasis and human disease. Cell Metab. 2017;25:285\u201399.","journal-title":"Cell Metab"},{"key":"460_CR139","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","volume":"142","author":"M Griffin","year":"2020","unstructured":"Griffin M, Rao VS, Ivey-Miranda J, Fleming J, et al. Empagliflozin in heart failure: diuretic and cardiorenal effects. Circulation. 2020;142:1028\u201339.","journal-title":"Circulation"},{"key":"460_CR140","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007048","volume":"14","author":"S Tamaki","year":"2021","unstructured":"Tamaki S, Yamada T, Watanabe T, et al. Effect of empagliflozin as an add-on therapy on decongestion and renal function in patients with diabetes hospitalized for acute decompensated heart failure: a prospective randomized controlled study. Circ Heart Fail. 2021;14:e007048.","journal-title":"Circ Heart Fail"},{"key":"460_CR141","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.009156","volume":"15","author":"M Omar","year":"2022","unstructured":"Omar M, Jensen J, Burkhoff D, et al. Effect of empagliflozin on blood volume redistribution in patients with chronic heart failure and reduced ejection fraction: an analysis from the Empire HF randomized clinical trial. Circ Heart Fail. 2022;15:e009156.","journal-title":"Circ Heart Fail"},{"key":"460_CR142","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/eurheartj\/ehac530","volume":"44","author":"J Biegus","year":"2023","unstructured":"Biegus J, Voors AA, Collins SP, et al. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. Eur Heart J. 2023;44:41\u201350.","journal-title":"Eur Heart J"},{"key":"460_CR143","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/dom.13126","volume":"20","author":"K Hallow","year":"2018","unstructured":"Hallow K, Helmlinger G, Greasly PJ, McMurray JJ, Boulton DW. Why do SGLT2 inhibitors reduce heart failure hospitalization?; a differential volume regulation hypothesis. Diabetes Obes Metab. 2018;20:479\u201387.","journal-title":"Diabetes Obes Metab"},{"key":"460_CR144","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","volume":"129","author":"D Cherney","year":"2014","unstructured":"Cherney D, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129:587\u201397.","journal-title":"Circulation"},{"key":"460_CR145","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","volume":"143","author":"M Nassif","year":"2021","unstructured":"Nassif M, Qintar M, Windsor SL, et al. Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF Trial. Circulation. 2021;143:1673\u201386.","journal-title":"Circulation"},{"key":"460_CR146","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1002\/ejhf.1328","volume":"20","author":"S Pabel","year":"2018","unstructured":"Pabel S, Wagner S, Bollenberg H, et al. Empagliflozin directly improves diastolic function in human heart failure. Eur J Heart Fail. 2018;20:1690\u2013700.","journal-title":"Eur J Heart Fail"},{"key":"460_CR147","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","volume":"139","author":"M Sano","year":"2019","unstructured":"Sano M, Goto S. Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation. 2019;139:1985\u20137.","journal-title":"Circulation"},{"key":"460_CR148","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1093\/cvr\/cvaa064","volume":"117","author":"M Packer","year":"2021","unstructured":"Packer M. Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: identification of a molecular link between their actions to stimulate erythrocytosis and to alleviate cellular stress. Cardiovasc Res. 2021;117:74\u201384.","journal-title":"Cardiovasc Res"},{"key":"460_CR149","first-page":"5","volume":"1","author":"H Kataoka","year":"2020","unstructured":"Kataoka H. Favorable effect of sodium-glucose cotransporter-2 inhibitor on respiratory function in type 2 diabetic patients. J Endocrine Dis Ther. 2020;1:5\u20139.","journal-title":"J Endocrine Dis Ther"},{"key":"460_CR150","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117\u201327.","journal-title":"N Engl J Med"},{"key":"460_CR151","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/ejhf.1673","volume":"22","author":"PM Seferovi\u0107","year":"2020","unstructured":"Seferovi\u0107 PM, Coats AJS, Ponikowski P, et al. European Society of Cardiology\/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. Eur J Heart Fail. 2020;22:196\u2013213.","journal-title":"Eur J Heart Fail"},{"key":"460_CR152","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000368266","volume":"128","author":"CA Wagner","year":"2014","unstructured":"Wagner CA. Effect of mineralocorticoids on acid\u2013base balance. Nephron Physiol. 2014;128:26\u201334.","journal-title":"Nephron Physiol"},{"key":"460_CR153","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nrneph.2013.110","volume":"9","author":"NJ Brown","year":"2013","unstructured":"Brown NJ. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol. 2013;9:459\u201369.","journal-title":"Nat Rev Nephrol"},{"key":"460_CR154","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/ki.1993.143","volume":"43","author":"S Eiam-Ong","year":"1993","unstructured":"Eiam-Ong S, Kurtzman NA, Sabatini S. Effect of furosemide-induced hypokalemic alkalosis on renal transport enzymes. Kidney Int. 1993;43:1015\u201320.","journal-title":"Kidney Int"},{"key":"460_CR155","doi-asserted-by":"publisher","first-page":"338","DOI":"10.7326\/0003-4819-90-3-338","volume":"90","author":"PA Gabow","year":"1979","unstructured":"Gabow PA, Moore S, Schrier RW. Spironolactone-induced hyperchloremic acidosis in cirrhosis. Ann Intern Med. 1979;90:338\u201340.","journal-title":"Ann Intern Med"},{"key":"460_CR156","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709\u201317.","journal-title":"N Engl J Med"},{"key":"460_CR157","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/ehjcvp\/pvw016","volume":"3","author":"B Pitt","year":"2017","unstructured":"Pitt B, Ferreira JP, Zannad F. Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives. Eur Heart J Cardiovasc Pharmacother. 2017;3:48\u201357.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"460_CR158","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43:474\u201384.","journal-title":"Eur Heart J"},{"key":"460_CR159","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","volume":"404","author":"PS Jhund","year":"2024","unstructured":"Jhund PS, Talebi A, Henderson AD, et al. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. Lancet. 2024;404:1119\u201331.","journal-title":"Lancet"},{"key":"460_CR160","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40119-022-00289-z","volume":"12","author":"NL Lariv\u00e9e","year":"2023","unstructured":"Lariv\u00e9e NL, Michaud JB, More KM, Wilson J-A, Tennankore KK. Hyperkalemia: prevalence, predictors and emerging treatments. Cardiol Ther. 2023;12:35\u201363.","journal-title":"Cardiol Ther"},{"key":"460_CR161","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1002\/ejhf.3423","volume":"26","author":"J Biegus","year":"2024","unstructured":"Biegus J, Cotter G, Metra M, Ponikowski P. Decongestion in acute heart failure: is it time to change diuretic-centered paradigm? Eur J Heart Fail. 2024;26:2094\u2013106.","journal-title":"Eur J Heart Fail"},{"key":"460_CR162","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/ejhf.2149","volume":"23","author":"M Packer","year":"2021","unstructured":"Packer M, McMurray JJV. Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction. Eur J Heart Fail. 2021;23:882\u201394.","journal-title":"Eur J Heart Fail"},{"key":"460_CR163","first-page":"504","volume":"7","author":"A Sharma","year":"2022","unstructured":"Sharma A, Verma S, Bhatt DL, et al. Optimizing foundational therapies in patients with HFrEF: how do we translate these findings into clinical care? JACC Basic Trans Science. 2022;7:504\u201317.","journal-title":"JACC Basic Trans Science"},{"key":"460_CR164","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","volume":"400","author":"A Mebazaa","year":"2022","unstructured":"Mebazaa A, Davison B, Cohen-Solal A, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022;400:1938\u201352.","journal-title":"Lancet"},{"key":"460_CR165","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s10741-023-10325-2","volume":"28","author":"J Malgie","year":"2023","unstructured":"Malgie J, Clephas PRD, Brunner-La Rocca H-P, de Boer RA, Brugts JJ. Guideline-directed medical therapy for HFrEF: sequential strategies and barriers for life-saving drug therapy. Heart Fail Rev. 2023;28:1221\u201334.","journal-title":"Heart Fail Rev"},{"key":"460_CR166","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacc.2024.01.029","volume":"83","author":"G Cotter","year":"2024","unstructured":"Cotter G, Davison B, Chioncel O. Enhanced decongestive therapy in patients with acute heart failure. J Am Coll Cardiol. 2024;83:1243\u201352.","journal-title":"J Am Coll Cardiol"},{"key":"460_CR167","volume":"11","author":"S Bratsos","year":"2019","unstructured":"Bratsos S. Efficacy of angiotensin converting enzyme inhibitors and angiotensin receptor-neprilysin inhibitors in the treatment of chronic heart failure: a review of landmark trials. Cureus. 2019;11:e3913.","journal-title":"Cureus"},{"key":"460_CR168","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1080\/00015385.2018.1455947","volume":"74","author":"FH Verbrugge","year":"2019","unstructured":"Verbrugge FH, Martens P, Ameloot K, et al. Spironolactone to increase natriuresis in congestive heart failure with cardiorenal syndrome. Acta Cardiol. 2019;74:100\u20137.","journal-title":"Acta Cardiol"},{"key":"460_CR169","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1161\/HYPERTENSIONAHA.122.19159","volume":"79","author":"Y Maeoka","year":"2022","unstructured":"Maeoka Y, Su X-T, Wang W-H, et al. Mineralocorticoid receptor antagonists cause natriuresis in the absence of aldosterone. Hypertension. 2022;79:1423\u201334.","journal-title":"Hypertension"},{"key":"460_CR170","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ejhf.799","volume":"19","author":"E D\u2019Elia","year":"2017","unstructured":"D\u2019Elia E, Iacovoni A, Vaduganathan M, Lorini FL, Perlini S, Senni M. Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides. Eur J Heart Fail. 2017;19:710\u20137.","journal-title":"Eur J Heart Fail"},{"key":"460_CR171","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609\u201320.","journal-title":"N Engl J Med"},{"key":"460_CR172","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/ejhf.3265","volume":"26","author":"A Mebazaa","year":"2024","unstructured":"Mebazaa A, Davison BA, Biegus J, et al. Reduced congestion and improved response to a fluid\/sodium challenge in chronic heart failure patients after initiation of sacubitril\/valsartan: the NATRIUM-HF study. Eur J Heart Fail. 2024;26:1507\u201317.","journal-title":"Eur J Heart Fail"},{"key":"460_CR173","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10741-024-10471-1","volume":"30","author":"P Rajzer","year":"2025","unstructured":"Rajzer P, Biegus J. Sacubitril\/valsartan in a wide spectrum of heart failure patients (from mechanisms of action to outcomes in specific populations). Heart Fail Rev. 2025;30:387\u2013405.","journal-title":"Heart Fail Rev"},{"key":"460_CR174","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/ejhf.2271","volume":"23","author":"G Savarese","year":"2021","unstructured":"Savarese G, Bodegard J, Norhammar A, et al. Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden). Eur J Heart Fail. 2021;23:1499\u2013511.","journal-title":"Eur J Heart Fail"},{"key":"460_CR175","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/ejhf.2703","volume":"25","author":"S Chatur","year":"2023","unstructured":"Chatur S, Claggett BL, Vardeny O, et al. Sacubitril\/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON-HF trial. Eur J Heart Fail. 2023;25:87\u201394.","journal-title":"Eur J Heart Fail"},{"key":"460_CR176","first-page":"449","volume":"10","author":"JM Vader","year":"2022","unstructured":"Vader JM, Givertz MM, Starling RC, et al. Tolerability of sacubitril\/valsartan in patients with advanced heart failure: analysis of the LIFE trial run-in. J Am Coll Cardiol HF. 2022;10:449\u201356.","journal-title":"J Am Coll Cardiol HF"},{"key":"460_CR177","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40256-024-00652-6","volume":"24","author":"L Spadafora","year":"2024","unstructured":"Spadafora L, Bernardi M, Sarto G, et al. Towards the fifth pillar for the treatment of heart failure with reduced ejection fraction: vericiguat in older and complex patients. Am J Cardiovasc Drugs. 2024;24:469\u201379.","journal-title":"Am J Cardiovasc Drugs"},{"key":"460_CR178","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1002\/ejhf.1835","volume":"22","author":"J Cautela","year":"2020","unstructured":"Cautela J, Tartiere J-M, Cohen-Solal A, et al. Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients. Eur J Heart Fail. 2020;22:1357\u201365.","journal-title":"Eur J Heart Fail"},{"key":"460_CR179","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","volume":"140","author":"M Nassif","year":"2019","unstructured":"Nassif M, Windsor SL, Tang F, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation. 2019;140:1463\u201376.","journal-title":"Circulation"},{"key":"460_CR180","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/ejhf.1713","volume":"22","author":"K Damman","year":"2020","unstructured":"Damman K, Beusekamp JC, Boorsma EM, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail. 2020;22:713\u201322.","journal-title":"Eur J Heart Fail"},{"key":"460_CR181","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1016\/j.jacc.2022.02.050","volume":"79","author":"M Fudim","year":"2022","unstructured":"Fudim M, Kaye DM, Borlaug BA, et al. Venous tone and stressed blood volume in heart failure. J Am Coll Cardiol. 2022;79:1858\u201369.","journal-title":"J Am Coll Cardiol"},{"key":"460_CR182","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/ejhf.59","volume":"16","author":"AA Voors","year":"2014","unstructured":"Voors AA, van Veldhuisen DJ, Robertson M, et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. Eur J Heart Fail. 2014;16:426\u201334.","journal-title":"Eur J Heart Fail"},{"key":"460_CR183","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/ejhf.121","volume":"16","author":"H-D D\u00fcngen","year":"2014","unstructured":"D\u00fcngen H-D, Musial-Bright L, Inkrot S, et al. Heart rate following short-term beta-blocker titration predicts all-cause mortality in elderly chronic heart failure patients: insights from the CIBIS-ELD trial. Eur J Heart Fail. 2014;16:907\u201314.","journal-title":"Eur J Heart Fail"},{"key":"460_CR184","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1253\/circj.CJ-21-0269","volume":"85","author":"K Kida","year":"2021","unstructured":"Kida K, Kitai T, Suzuki N, et al. Prognostic implications of reduction in heart rates in patients with acute heart failure and atrial fibrillation. Circ J. 2021;85:1869\u201375.","journal-title":"Circ J"},{"key":"460_CR185","doi-asserted-by":"publisher","first-page":"2262073","DOI":"10.1080\/20016689.2023.2262073","volume":"11","author":"ZM Khan","year":"2023","unstructured":"Khan ZM, Briere JB, Olewinska E, Khrouf F, Nikodem M. Ivabradine in patients with heart failure: a systematic literature review. J Mark Access Health Policy. 2023;11:2262073.","journal-title":"J Mark Access Health Policy"},{"key":"460_CR186","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1056\/NEJMoa0907118","volume":"362","author":"D De Backer","year":"2010","unstructured":"De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362:779\u201389.","journal-title":"N Engl J Med"},{"key":"460_CR187","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/ejhf.991","volume":"20","author":"A Mebazaa","year":"2018","unstructured":"Mebazaa A, Montiejunaite J, Gayat E, et al. Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long-Term Registry. Eur J Heart Fail. 2018;20:332\u201341.","journal-title":"Eur J Heart Fail"},{"key":"460_CR188","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1056\/NEJMoa2026845","volume":"385","author":"R Mathew","year":"2021","unstructured":"Mathew R, di Santo P, Jung RG, et al. Milrinone as compared with dobutamine in the treatment of cardiogenic shock. N Engl J Med. 2021;385:516\u201325.","journal-title":"N Engl J Med"},{"key":"460_CR189","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1002\/ehf2.14379","volume":"10","author":"E Rodenas-Alesina","year":"2023","unstructured":"Rodenas-Alesina E, Scolari FL, Wang VN, et al. Improved mortality and haemodynamics with milrinone in cardiogenic shock due to acute decompensated heart failure. ESC Heart Fail. 2023;10:2577\u201387.","journal-title":"ESC Heart Fail"},{"key":"460_CR190","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1161\/CIRCULATIONAHA.124.070105","volume":"150","author":"C Daubert","year":"2024","unstructured":"Daubert C, Linde C. Cardiac resynchronization therapy: new perspectives. Circulation. 2024;150:1563\u20136.","journal-title":"Circulation"},{"key":"460_CR191","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000527204","volume":"13","author":"A Kazory","year":"2023","unstructured":"Kazory A, Sgarabotto L, Ronco C. Extracorporeal ultrafiltration for acute heart failure. Cardiorenal Med. 2023;13:1\u20138.","journal-title":"Cardiorenal Med"},{"key":"460_CR192","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1161\/CIRCHEARTFAILURE.108.821785","volume":"2","author":"GM Felker","year":"2009","unstructured":"Felker GM, O\u2019Connor CM, Braunwald E, for the Heart Failure Clinical Research Network Investigators. Loop diuretics in acute decompensated heart failure: necessary? evil? a necessary evil? Circ Heart Fail. 2009;2:56\u201362.","journal-title":"Circ Heart Fail"},{"key":"460_CR193","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nrcardio.2014.215","volume":"12","author":"JM ter Maaten","year":"2015","unstructured":"ter Maaten JM, Valente MAE, Damman K, Hillege HL, Navis G, Voors AA. Diuretic response in acute heart failure: pathophysiology, evaluation, and therapy. Nat Rev Cardiol. 2015;12:184\u201392.","journal-title":"Nat Rev Cardiol"},{"key":"460_CR194","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1159\/000164149","volume":"113","author":"WF Peacock","year":"2009","unstructured":"Peacock WF, Costanzo MR, De Marco T, et al. Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: Insights from the ADHERE registry. Cardiology. 2009;113:12\u20139.","journal-title":"Cardiology"},{"key":"460_CR195","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1161\/CIRCHEARTFAILURE.113.000895","volume":"7","author":"JM Testani","year":"2014","unstructured":"Testani JM, Brisco MA, Turner JM, et al. Loop diuretic efficacy: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail. 2014;7:261\u201370.","journal-title":"Circ Heart Fail"},{"key":"460_CR196","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1159\/000047397","volume":"96","author":"DH Ellison","year":"2001","unstructured":"Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology. 2001;96:132\u201343.","journal-title":"Cardiology"},{"key":"460_CR197","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1159\/000502648","volume":"44","author":"C Masella","year":"2019","unstructured":"Masella C, Viggiano D, Molfino I, et al. Diuretic resistance in cardio-nephrology: role of pharmacokinetics, hypochloremia, and kidney remodeling. Kidney Blood Press Res. 2019;44:915\u201327.","journal-title":"Kidney Blood Press Res"},{"key":"460_CR198","first-page":"97","volume":"3","author":"RJ Mentz","year":"2015","unstructured":"Mentz RJ, Stevens SR, DeVore AD, et al. Decongestion strategies and renin\u2013angiotensin\u2013aldosterone system activation in acute heart failure. J Am Coll Cardiol HF. 2015;3:97\u2013107.","journal-title":"J Am Coll Cardiol HF"},{"key":"460_CR199","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.3390\/jcm8111854","volume":"8","author":"G Rucco","year":"2019","unstructured":"Rucco G, Feola M, Nuti R, Luschi L, Evangelista I, Palazzuoli A. Loop diuretic administration in patients with acute heart failure and reduced systolic function: effects of different intravenous diuretic dosed and diuretic response measurements. J Clin Med. 2019;8:1854.","journal-title":"J Clin Med"},{"key":"460_CR200","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.amjcard.2016.09.014","volume":"119","author":"JL Grodin","year":"2017","unstructured":"Grodin JL, Sun J-L, Anstrom KJ, et al. Implications of serum chloride homeostasis in acute heart failure (from ROSE-AHF). Am J Cardiol. 2017;119:78\u201383.","journal-title":"Am J Cardiol"},{"key":"460_CR201","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003180","volume":"9","author":"JS Hanberg","year":"2016","unstructured":"Hanberg JS, Rao V, ter Maaten JM, et al. Hypochloremia and diuretic resistance in heart failure: mechanistic insights. Circ Heart Fail. 2016;9:e003180.","journal-title":"Circ Heart Fail"},{"key":"460_CR202","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2022.100465","volume":"4","author":"JG Amatruda","year":"2022","unstructured":"Amatruda JG, Scherzer R, Rao VS, et al. Renin\u2013angiotensin\u2013aldosterone system activation and diuretic response in ambulatory patients with heart failure. Kidney Med. 2022;4:100465.","journal-title":"Kidney Med"},{"key":"460_CR203","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1681\/ASN.2016111178","volume":"28","author":"VS Rao","year":"2017","unstructured":"Rao VS, Planavsky N, Hanberg JS, et al. Compensatory distal reabsorption drives diuretic resistance in human heart failure. J Am Soc Nephrol. 2017;28:3414\u201324.","journal-title":"J Am Soc Nephrol"},{"key":"460_CR204","doi-asserted-by":"publisher","first-page":"4468","DOI":"10.1093\/eurheartj\/ehab620","volume":"42","author":"ZL Cox","year":"2021","unstructured":"Cox ZL, Rao VS, Ivey-Miranda JB, et al. Compensatory post-diuretic renal sodium reabsorption is not a dominant mechanism of diuretic resistance in acute heart failure. Eur Heart J. 2021;42:4468\u201377.","journal-title":"Eur Heart J"},{"key":"460_CR205","first-page":"383","volume":"7","author":"DZ Hodson","year":"2019","unstructured":"Hodson DZ, Griffin M, Mahoney D, et al. Natriuretic response is highly variable and associated with 6-month survival: insights from the ROSE-AHF trial. J Am Coll Cardiol HF. 2019;7:383\u201391.","journal-title":"J Am Coll Cardiol HF"},{"key":"460_CR206","first-page":"404","volume":"7","author":"P Martens","year":"2019","unstructured":"Martens P, Dupont M, Verbrugge FH, et al. Urinary sodium profiling in chronic heart failure to detect development of acute decompensated heart failure. J Am Coll Cardiol HF. 2019;7:404\u201314.","journal-title":"J Am Coll Cardiol HF"},{"key":"460_CR207","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/ejhf.1428","volume":"21","author":"J Biegus","year":"2019","unstructured":"Biegus J, Zymli\u0144ski R, Sokolski M, et al. Serial assessment of spot urine sodium predicts effectiveness of decongestion and outcome in patients with acute heart failure. Eur J Heart Fail. 2019;21:624\u201333.","journal-title":"Eur J Heart Fail"},{"key":"460_CR208","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1002\/ejhf.1753","volume":"22","author":"K Damman","year":"2020","unstructured":"Damman K, ter Maaten JM, Coster JE, et al. Clinical importance of urinary sodium excretion in acute heart failure. Eur J Heart Fail. 2020;22:1438\u201347.","journal-title":"Eur J Heart Fail"},{"key":"460_CR209","doi-asserted-by":"publisher","first-page":"886","DOI":"10.7326\/0003-4819-114-10-886","volume":"114","author":"DH Ellison","year":"1991","unstructured":"Ellison DH. The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann Intern Med. 1991;114:886\u201394.","journal-title":"Ann Intern Med"},{"key":"460_CR210","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.jacc.2010.06.034","volume":"56","author":"JC Jentzer","year":"2010","unstructured":"Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol. 2010;56:1527\u201334.","journal-title":"J Am Coll Cardiol"},{"key":"460_CR211","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/eurheartj\/ehac689","volume":"44","author":"JC Trull\u00e1s","year":"2023","unstructured":"Trull\u00e1s JC, Morales-Rull JL, Casado J, et al. Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. Eur Heart J. 2023;44:411\u201321.","journal-title":"Eur Heart J"},{"key":"460_CR212","volume":"15","author":"A Gogikar","year":"2023","unstructured":"Gogikar A, Nanda A, Janga L, et al. Combination diuretic therapy with thiazides: a systematic review on the beneficial approach to overcome refractory fluid overload in heart failure. Cureus. 2023;15:e44624.","journal-title":"Cureus"},{"key":"460_CR213","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1253\/circj.CJ-13-1255","volume":"78","author":"A Shirakabe","year":"2014","unstructured":"Shirakabe A, Hata N, Yamamoto M, et al. Immediate administration of tolvaptan prevents the exacerbation of acute kidney injury and improves the mid-term prognosis of patients with severely decompensated acute heart failure. Circ J. 2014;78:911\u201321.","journal-title":"Circ J"},{"key":"460_CR214","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1253\/circj.CJ-17-0179","volume":"82","author":"T Inomata","year":"2018","unstructured":"Inomata T, Ikeda Y, Kida K, et al. Effects of additive tolvaptan vs. increased furosemide on heart failure with diuretic resistance and renal impairment: results from the K-STAR study. Circ J. 2018;82:159\u201367.","journal-title":"Circ J"},{"key":"460_CR215","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1161\/CIRCULATIONAHA.122.059038","volume":"146","author":"PC Schulze","year":"2022","unstructured":"Schulze PC, Bogoviku J, Westphal J, et al. Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF). Circulation. 2022;146:289\u201398.","journal-title":"Circulation"},{"key":"460_CR216","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","volume":"28","author":"AA Voors","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28:568\u201374.","journal-title":"Nat Med"},{"key":"460_CR217","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jacc.2024.02.009","volume":"83","author":"ZL Cox","year":"2024","unstructured":"Cox ZL, Collins SP, Hernandez GA, et al. Efficacy and safety of dapagliflozin in patients with acute heart failure. J Am Coll Cardiol. 2024;83:1295\u2013306.","journal-title":"J Am Coll Cardiol"},{"key":"460_CR218","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/ejhf.2584","volume":"24","author":"D Vukadinovi\u0107","year":"2022","unstructured":"Vukadinovi\u0107 D, Abdin A, Anker SD, et al. Side effects and treatment inhibition barriers of sodium-glucose cotransporter 2 inhibitors in heart failure: a systematic review and meta-analysis. Eur J Heart Fail. 2022;24:1625\u201332.","journal-title":"Eur J Heart Fail"},{"key":"460_CR219","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.jacc.2022.01.029","volume":"79","author":"JP Ferreira","year":"2022","unstructured":"Ferreira JP, Butler J, Zannad F, et al. Mineralocorticoid receptor antagonists and empagliflozin in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol. 2022;79:1129\u201337.","journal-title":"J Am Coll Cardiol"},{"key":"460_CR220","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1159\/000515604","volume":"11","author":"FB Rivera","year":"2021","unstructured":"Rivera FB, Alfonso P, Golbin JM, et al. The role of serum chloride in acute and chronic heart failure: a narrative review. Cardiorenal Med. 2021;11:87\u201398.","journal-title":"Cardiorenal Med"},{"key":"460_CR221","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2459\/JCM.0000000000001644","volume":"25","author":"K Stankowski","year":"2024","unstructured":"Stankowski K, Villaschi A, Tartaglia F, et al. Prognostic value of hypochloremia on mortality in patients with heart failure: a systematic review and meta-analysis. J Cardiovasc Med. 2024;25:499\u2013510.","journal-title":"J Cardiovasc Med"},{"key":"460_CR222","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1253\/circj.CJ-17-0938","volume":"82","author":"T Kondo","year":"2018","unstructured":"Kondo T, Yamada T, Tamaki S, et al. Serial change in serum chloride during hospitalization could predict heart failure death in acute decompensated heart failure patients. Circ J. 2018;82:1041\u201350.","journal-title":"Circ J"},{"key":"460_CR223","first-page":"43","volume":"11","author":"JJ Cuthbert","year":"2022","unstructured":"Cuthbert JJ, Brown OI, Urbinati A, et al. Hypochloraemia following admission to hospital with heart failure is common and associated with an increased risk of readmission or death: a report from OPERA-HF. Eur Heart J Acute Cardiovasc Care. 2022;11:43\u201352.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"460_CR224","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ijcard.2022.12.041","volume":"375","author":"S Kurashima","year":"2023","unstructured":"Kurashima S, Kitai T, Matsue Y, et al. Trajectory of serum chloride levels during decongestive therapy in acute heart failure. Int J Cardiol. 2023;375:36\u201343.","journal-title":"Int J Cardiol"},{"key":"460_CR225","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3390\/nu15020395","volume":"15","author":"A Bernal","year":"2023","unstructured":"Bernal A, Zafra MA, Sim\u00f3n MJ, Mah\u00eda J. Sodium homeostasis, a balance necessary for life. Nutrients. 2023;15:395.","journal-title":"Nutrients"},{"key":"460_CR226","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40635-018-0174-5","volume":"6","author":"CA Pfortmueller","year":"2018","unstructured":"Pfortmueller CA, Uehlinger D, von Haehling S, Schefold JC. Serum chloride levels in critical illness: the hidden story. Intensive Care Med Exp. 2018;6:10.","journal-title":"Intensive Care Med Exp"},{"key":"460_CR227","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/ejhf.2053","volume":"23","author":"J Biegus","year":"2021","unstructured":"Biegus J, Zymli\u0144ski R, Testani J, et al. Renal profiling based on estimated glomerular filtration rate and spot urine sodium identifies high-risk acute heart failure patients. Eur J Heart Fail. 2021;23:729\u201339.","journal-title":"Eur J Heart Fail"},{"key":"460_CR228","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1038\/s41591-023-02532-z","volume":"29","author":"JM ter Maaten","year":"2023","unstructured":"ter Maaten JM, Beldhuis IE, van der Meer P, et al. Natriuresis-guided diuretic therapy in acute heart failure: a pragmatic randomized trial. Nat Med. 2023;29:2625\u201332.","journal-title":"Nat Med"},{"key":"460_CR229","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.1016\/j.jacc.2014.11.025","volume":"65","author":"P Nijst","year":"2015","unstructured":"Nijst P, Verbrugge FH, Grieten L, et al. The pathophysiological role of interstitial sodium in heart failure. J Am Coll Cardiol. 2015;65:3783\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"460_CR230","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004763","volume":"11","author":"P Nijst","year":"2018","unstructured":"Nijst P, Olinevich M, Hilkens P, et al. Dermal interstitial alterations in patients with heart failure and reduced ejection fraction: a potential contributor to fluid accumulation? Circ Heart Fail. 2018;11:e004763.","journal-title":"Circ Heart Fail"},{"key":"460_CR231","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.121.012910","volume":"14","author":"S Lemoine","year":"2021","unstructured":"Lemoine S, Salerno FR, Akbari A, McKelvie RS, McIntyre CW. Tissue sodium storage in patients with heart failure: a new therapeutic target? Circ Cardiovasc Imaging. 2021;14:e012910.","journal-title":"Circ Cardiovasc Imaging"},{"key":"460_CR232","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/ejhf.3131","volume":"26","author":"J Dauw","year":"2024","unstructured":"Dauw J, Meekers E, Martens P, et al. Sodium loading in ambulatory patients with heart failure with reduced ejection fraction: mechanistic insights into sodium handling. Eur J Heart Fail. 2024;26:616\u201324.","journal-title":"Eur J Heart Fail"},{"key":"460_CR233","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1681\/ASN.2016060662","volume":"28","author":"MP Schneider","year":"2017","unstructured":"Schneider MP, Raff U, Kopp C, et al. Skin sodium concentration correlates with left ventricular hypertrophy in CKD. J Am Soc Nephrol. 2017;28:1867\u201376.","journal-title":"J Am Soc Nephrol"},{"key":"460_CR234","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13613-018-0442-2","volume":"8","author":"L Hessels","year":"2018","unstructured":"Hessels L, Lansink-Hartgring AO, Zellemaker-Hoekstra M, Nijsten MW. Estimation of sodium and chloride storage in critically ill patients: a balance study. Ann Intensive Care. 2018;8:97.","journal-title":"Ann Intensive Care"},{"key":"460_CR235","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.cardfail.2021.07.003","volume":"27","author":"P Bjornstad","year":"2021","unstructured":"Bjornstad P, Greasley PJ, Wheeler DC, et al. The potential roles of osmotic and nonosmotic sodium handling in mediating the effects of sodium-glucose cotransporter 2 inhibitors on heart failure. J Card Fail. 2021;27:1447\u201355.","journal-title":"J Card Fail"},{"key":"460_CR236","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/nep.13674","volume":"25","author":"Y Komaru","year":"2020","unstructured":"Komaru Y, Doi K. Urinary chloride concentration as a prognostic marker in critically ill patients. Nephrology (Carlton). 2020;25:384\u20139.","journal-title":"Nephrology (Carlton)"},{"key":"460_CR237","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3390\/life13030698","volume":"13","author":"A Xanthopoulos","year":"2023","unstructured":"Xanthopoulos A, Christofidis C, Pantsios C, et al. The prognostic role of spot urinary sodium and chloride in a cohort of hospitalized advanced heart failure patients: a pilot study. Life. 2023;13:698.","journal-title":"Life"},{"key":"460_CR238","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/ehf2.15054","volume":"12","author":"M Guzik","year":"2025","unstructured":"Guzik M, Zymli\u0144ski R, Ponikowski P, Biegus J. Urine chloride trajectory and relationship with diuretic response in acute heart failure. ESC Heart Fail. 2025;12:133\u201341.","journal-title":"ESC Heart Fail"},{"key":"460_CR239","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1253\/circj.CJ-10-0869","volume":"74","author":"K Kee","year":"2010","unstructured":"Kee K, Naughton MT. Heart failure and the lung. Circ J. 2010;74:2507\u201316.","journal-title":"Circ J"},{"key":"460_CR240","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jjcc.2012.06.004","volume":"60","author":"A Shirakabe","year":"2012","unstructured":"Shirakabe A, Hata N, Kobayashi N, et al. Clinical significance of acid\u2013base balance in an emergency setting in patients with acute heart failure. J Cardiol. 2012;60:288\u201394.","journal-title":"J Cardiol"},{"key":"460_CR241","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.jacc.2015.04.024","volume":"65","author":"F Husain-Syed","year":"2015","unstructured":"Husain-Syed F, McCullough PA, Birk H-W, et al. Cardio-pulmonary-renal interactions: a multidisciplinary approach. J Am Coll Cardiol. 2015;65:2433\u201348.","journal-title":"J Am Coll Cardiol"},{"key":"460_CR242","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/cc11323","volume":"16","author":"N Heming","year":"2012","unstructured":"Heming N, Urien S, Faisy C. Acetazolamide: a second wind for a respiratory stimulant in the intensive care unit? Crit Care. 2012;16:318.","journal-title":"Crit Care"},{"issue":"8","key":"460_CR243","first-page":"01","volume":"14","author":"R Hadano","year":"2025","unstructured":"Hadano R, Kataoka H, Sato I, Abe H, Yamasaki Y, Sugata T. Improved respiratory function by SGLT2 inhibitor treatment in a patient with obstructive pulmonary disease complicated by heart failure. EC Pulmonology and Respiratory Medicine. 2025;14(8):01\u20136.","journal-title":"EC Pulmonology and Respiratory Medicine"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00460-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-026-00460-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00460-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:03:06Z","timestamp":1788411786000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-026-00460-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":243,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["460"],"URL":"https:\/\/doi.org\/10.1007\/s40119-026-00460-w","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"13 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Hajime Kataoka has no conflicts of interest to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}